ACC.25 – In STRIDE, the GLP-1RA semaglutide reduced maximal walking distance, symptoms and QoL in patients with PAD and T2D compared with placebo. “This represents a new therapeutic option for patients with PAD and T2D,” says Marc Bonaca.
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25 – In STRIDE, the GLP-1RA semaglutide reduced maximal walking distance, symptoms and QoL in patients with PAD and T2D compared with placebo. “This represents a new therapeutic option for patients with PAD and T2D,” says Marc Bonaca.
Restart
Resume
Transcript
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Aurora, CO, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 April 2025
Read our summary of the STRIDE trial
The findings of this study were simultaneously published in The Lancet
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Recommended
Details
Presenters
Overview
ACC.25 – In STRIDE, the GLP-1RA semaglutide reduced maximal walking distance, symptoms and QoL in patients with PAD and T2D compared with placebo. “This represents a new therapeutic option for patients with PAD and T2D,” says Marc Bonaca.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Aurora, CO, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 1 April 2025
Read our summary of the STRIDE trial
The findings of this study were simultaneously published in The Lancet
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
0.50 credits
<p>IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base</p>
MinuteCE®
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
1.00 credits
<p>Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?